Abivax S.A. (ABVX) Stock
ABVX Key Statistics
About Abivax S.A.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
CEO: Marc de Garidel. Company website
ABVX — Frequently Asked Questions
What is the ABVX stock price today?
Abivax S.A. (ABVX) trades at $105.04, down 1.82% on the day, as of Sep 20, 2026 14:57 UTC.
What is Abivax S.A.'s market cap?
Abivax S.A. has a market capitalisation of $7.71B, calculated from the live ABVX share price and shares outstanding.
What is the P/E ratio of ABVX?
ABVX has no meaningful price-to-earnings ratio: Abivax S.A. lost $3.69 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Abivax S.A. make?
Abivax S.A. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for ABVX?
ABVX has traded between $69.81 and $148.83 over the past 52 weeks, and the last price is 29.4% below that high.
Is Abivax S.A. profitable?
Yes. Abivax S.A. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for ABVX?
Wall Street analysts rate ABVX Buy, with an average price target of $153.00, 45.7% above the current price.
What sector is Abivax S.A. in?
Abivax S.A. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in FR.
Who is the CEO of Abivax S.A.?
Marc de Garidel is the chief executive of Abivax S.A., which employs 80 people.
Where can I track ABVX in real time?
QFI Terminal shows ABVX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ABVX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ABVX in Terminal See plans